Advances in Allogeneic Chimeric Antigen Receptor T Cells.
10.3881/j.issn.1000-503X.15325
- VernacularTitle:异基因嵌合抗原受体T细胞技术的研究进展
- Author:
Qian ZHAO
1
;
Feng LI
1
Author Information
1. Department of Hematology,General Hospital of Eastern Theater Command of the Chinese PLA,Nanjing 210002,China.
- Publication Type:Journal Article
- Keywords:
advance;
allogeneic;
chimeric antigen receptor T cell
- MeSH:
Humans;
Receptors, Chimeric Antigen;
T-Lymphocytes;
Neoplasms;
Immunotherapy, Adoptive;
Graft vs Host Disease/therapy*;
Hematopoietic Stem Cell Transplantation
- From:
Acta Academiae Medicinae Sinicae
2023;45(6):967-972
- CountryChina
- Language:Chinese
-
Abstract:
Autologous chimeric antigen receptor(CAR)T-cell therapy has improved the prognosis of hematological malignancies.Nevertheless,allogeneic CAR-T cells have potential advantages over the autologous approach available on the market.However,allogeneic CAR-T cells may cause life-threatening graft-versus-host disease(GVHD)or be rapidly eliminated by the host immune system.In this review,we analyze the different sources of T cells for optimal allogeneic CAR-T cell therapy,describe the different approaches,and introduce the gene editing measures to produce allogeneic CAR-T cells with limited potential for GVHD and improved anti-tumor effect.
